A genomic perspective on human proteases as drug targets.
about
Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteasesSymplocamide A, a potent cytotoxin and chymotrypsin inhibitor from the marine Cyanobacterium Symploca spDefining the extended substrate specificity of kallikrein 1-related peptidases.New concepts in molecular imaging: non-invasive MRI spotting of proteolysis using an Overhauser effect switch.Characterization and expression analysis of chymotrypsin after bacterial challenge in the mud crab, Scylla paramamosain.The extended cleavage specificity of human thrombin.Mutations in Arg143 and Lys192 of the Human Mast Cell Chymase Markedly Affect the Activity of Five Potent Human Chymase Inhibitors.High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitorsHuman tissue kallikreins: a new enzymatic cascade pathway?Managing peptidases in the genomic era.Exploitation of silicon medicinal chemistry in drug discovery.HIV protease inhibitors and nuclear lamin processing: getting the right bells and whistles.Chemistry and biology of multicomponent reactions.Protease sensing with nanoparticle based platforms.In Vitro Selection of Cathepsin E-Activity-Enhancing Peptide Aptamers at Neutral pH.Unusual phyletic distribution of peptidases as a tool for identifying potential drug targets.In vivo Overhauser-enhanced MRI of proteolytic activity.Catalase-Loaded TaOx Nanoshells as Bio-Nanoreactors Combining High-Z Element and Enzyme Delivery for Enhancing Radiotherapy.
P2860
Q24298613-01484193-D1BA-4191-BAF0-F0A1DC883C4CQ24633205-19C10733-76A8-4AB6-9958-0CA1C91A247DQ33304675-32BC623E-A766-4255-B025-2CA62BA42167Q33435387-B27B46F4-B271-467B-BC8A-EFD6FF8F9A65Q33890353-4382A1A3-2A3C-49EC-B2D8-FD6FE49F79C4Q34181932-A8E325EC-ABC2-48DA-9C3A-0DA90C94AB3AQ34804843-6E647BA3-A0B7-4D8F-9B96-AA8326E6BE7FQ34987358-3329B8F7-1E69-4184-B7B7-EAE44384A424Q35000702-C8C4CA8C-0AEF-4315-9C7B-D51DFC850C7FQ35187221-134F2373-068F-482A-9B0B-BE1866D645D6Q35871923-61AC6976-A811-4A5A-AA06-A5C00C5070BFQ35956709-DEE04A40-4425-402A-8566-B4D02C14332DQ37017587-F68C29EF-DB9E-4C2E-802E-1B195C4631F1Q37793922-A3ABFBEB-6DC4-45A6-8125-95327C120B8FQ42093114-92714FCA-2C87-4841-B6BA-43BAE10C9C0FQ42924470-0DD75389-F35F-42E7-9671-C1D58F1BB7E4Q53057977-D5137376-1670-418E-8420-1A61A1B9D1BFQ53782069-3C7A175E-F641-4DAC-BCF7-E3E89BF153AA
P2860
A genomic perspective on human proteases as drug targets.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A genomic perspective on human proteases as drug targets.
@ast
A genomic perspective on human proteases as drug targets.
@en
type
label
A genomic perspective on human proteases as drug targets.
@ast
A genomic perspective on human proteases as drug targets.
@en
prefLabel
A genomic perspective on human proteases as drug targets.
@ast
A genomic perspective on human proteases as drug targets.
@en
P1433
P1476
A genomic perspective on human proteases as drug targets.
@en
P304
P356
10.1016/S1359-6446(01)01793-7
P577
2001-07-01T00:00:00Z